Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review

被引：74

作者：

Gomez-Lopez, A ^{[1
]}

Mellado, E ^{[1
]}

Rodriguez-Tudela, JL ^{[1
]}

Cuenca-Estrella, M ^{[1
]}

机构：

[1] Inst Salud Carlos III, Ctr Nacl Microbiol, Serv Micol, Madrid 28220, Spain

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2005年 / 55卷 / 03期

关键词：

Rhodotorula; susceptibility of emerging yeasts; fluconazole resistance; ravuconazole;

D O I：

10.1093/jac/dki020

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objective: In vitro susceptibility results of 29 clinical isolates of Rhodotorula spp. were analysed. In addition, the susceptibility profile of another 102 Rhodotorula isolates was reviewed. Methods: The review included studies using antifungal susceptibility testing reference procedures or commercial methods exhibiting high correlation rates with reference procedures (Etest and Sensititre YeastOne). The 131 organisms analysed were 77 Rhodotorula mucilaginosa, 45 Rhodotorula glutinis and nine Rhodotorula spp. Results and conclusions: Fluconazole, itraconazole and voriconazole were inactive in vitro against the majority of isolates. Amphotericin B and flucytosine exhibited good activity, being reasonable alternatives for empirical treatment. Ravuconazole was more active in vitro than other azole agents and it could be considered as an extended-spectrum triazole and maybe as a therapeutic alternative in treating infections caused by Rhodotorula species.

引用

页码：312 / 316

页数：5

共 24 条

[1]

Anatoliotaki Maria, 2003, Clin Lab, V49, P49

[2]

BRAUN DK, 1992, MYCOSES, V35, P305, DOI 10.1111/j.1439-0507.1992.tb00882.x

[3]

Carrillo-Munoz A J, 1999, Rev Esp Quimioter, V12, P126

[4] Present status of the detection of antifungal resistance:: the perspective from both sides of the ocean [J].

Cuenca-Estrella, M ;

Rodríguez-Tudela, JL .

CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 :46-53

[5] Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species [J].

Cuenca-Estrella, M ;

Lee-Yang, W ;

Ciblak, MA ;

Arthington-Skaggs, BA ;

Mellado, E ;

Warnock, DW ;

Rodriguez-Tudela, JL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3644-3647

[6] In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens [J].

Espinel-Ingroff, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) :198-202

[7] Multicenter comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory Standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms [J].

Espinel-Ingroff, A ;

Pfaller, M ;

Messer, SA ;

Knapp, CC ;

Killian, S ;

Norris, HA ;

Ghannoum, MA .

JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (03) :591-595

[8] Microbiological characteristics and susceptibility patterns of strains of rhodotorula isolated from clinical samples [J].

Galán-Sánchez, F ;

García-Martos, P ;

Rodríguez-Ramos, C ;

Marín-Casanova, P ;

Mira-Gutiérrez, J .

MYCOPATHOLOGIA, 1999, 145 (03) :109-112

[9] Antifungal susceptibility of emerging yeast pathogens [J].

García-Martos, P ;

Domínguez, I ;

Marín, P ;

García-Agudo, R ;

Mira, SAYJ .

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2001, 19 (06) :249-256

[10] Catheter-related sepsis due to Rhodotorula glutinis [J].

Hsueh, PR ;

Teng, LJ ;

Ho, SW ;

Luh, KT .

JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (02) :857-859

← 1 2 3 →